FI103712B1 - Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi - Google Patents

Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi

Info

Publication number
FI103712B1
FI103712B1 FI902553A FI902553A FI103712B1 FI 103712 B1 FI103712 B1 FI 103712B1 FI 902553 A FI902553 A FI 902553A FI 902553 A FI902553 A FI 902553A FI 103712 B1 FI103712 B1 FI 103712B1
Authority
FI
Finland
Prior art keywords
homogeneous
porous
preparing
novel
dosage form
Prior art date
Application number
FI902553A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI902553A0 (fi
FI103712B (fi
Inventor
Frederic Courteille
Magali Vanhoeve
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Publication of FI902553A0 publication Critical patent/FI902553A0/fi
Application granted granted Critical
Publication of FI103712B publication Critical patent/FI103712B/fi
Publication of FI103712B1 publication Critical patent/FI103712B1/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI902553A 1989-05-24 1990-05-23 Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi FI103712B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation
FR8906781 1989-05-24

Publications (3)

Publication Number Publication Date
FI902553A0 FI902553A0 (fi) 1990-05-23
FI103712B FI103712B (fi) 1999-08-31
FI103712B1 true FI103712B1 (fi) 1999-08-31

Family

ID=9381955

Family Applications (1)

Application Number Title Priority Date Filing Date
FI902553A FI103712B1 (fi) 1989-05-24 1990-05-23 Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi

Country Status (24)

Country Link
US (1) US5244881A (show.php)
EP (2) EP0399902B1 (show.php)
JP (1) JP2948271B2 (show.php)
KR (1) KR0163423B1 (show.php)
AT (2) ATE98867T1 (show.php)
AU (2) AU623779B2 (show.php)
CA (2) CA2017360A1 (show.php)
DD (1) DD297915A5 (show.php)
DE (2) DE69000641T2 (show.php)
DK (2) DK0399903T3 (show.php)
ES (2) ES2062437T3 (show.php)
FI (1) FI103712B1 (show.php)
FR (1) FR2647343B1 (show.php)
GR (1) GR3006655T3 (show.php)
IE (2) IE64370B1 (show.php)
IL (2) IL94459A (show.php)
NO (1) NO180517C (show.php)
NZ (2) NZ233766A (show.php)
PL (1) PL285327A1 (show.php)
PT (2) PT94138B (show.php)
TW (1) TW257672B (show.php)
WO (1) WO1990014089A1 (show.php)
YU (1) YU100790A (show.php)
ZA (2) ZA903895B (show.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
NZ246091A (en) 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
CA2281473C (en) * 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
US20050038039A1 (en) 2002-01-15 2005-02-17 Domenico Fanara Formulations
AU2003215396B2 (en) 2002-02-25 2010-04-08 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
KR101570131B1 (ko) 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 말초혈관질환 치료와 예방을 위한 용도
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
JP2011502125A (ja) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 小分子拡散を促進する新しい種類の治療法
ES2564056T3 (es) * 2008-09-05 2016-03-17 Johnson & Johnson Consumer Inc. Método para hacer pastillas de cetirizina
CN108464976A (zh) 2009-06-22 2018-08-31 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
WO2011152869A1 (en) 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP5890951B2 (ja) * 2010-09-13 2016-03-22 ベヴ−アールエックス、インク. 不快味マスキング剤を有する水性薬物送達システム
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
CN115089569A (zh) 2016-03-24 2022-09-23 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (show.php) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
JPS61267555A (ja) * 1984-11-27 1986-11-27 Dainippon Pharmaceut Co Ltd キノリン誘導体及びそれを有効成分とする抗潰瘍剤
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
DE69005359D1 (de) 1994-02-03
ATE98867T1 (de) 1994-01-15
FI902553A0 (fi) 1990-05-23
WO1990014089A1 (fr) 1990-11-29
AU5743390A (en) 1990-12-18
FR2647343B1 (fr) 1994-05-06
IL94459A0 (en) 1991-03-10
NO902280L (no) 1990-11-26
NO902280D0 (no) 1990-05-23
PT94138B (pt) 1996-12-31
US5244881A (en) 1993-09-14
AU631888B2 (en) 1992-12-10
DD297915A5 (de) 1992-01-30
NZ233784A (en) 1993-04-28
DE69000641T2 (de) 1993-06-09
DK0399903T3 (da) 1993-02-08
IE64370B1 (en) 1995-07-26
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
CA2017360A1 (fr) 1990-11-24
PL285327A1 (en) 1991-02-11
ES2062437T3 (es) 1994-12-16
DE69005359T2 (de) 1994-05-05
EP0399902B1 (fr) 1993-12-22
EP0399903A1 (fr) 1990-11-28
ZA903978B (en) 1991-03-27
NO180517C (no) 1997-05-07
IL94459A (en) 1995-01-24
IL94460A0 (en) 1991-03-10
DK0399902T3 (da) 1994-02-14
PT94138A (pt) 1991-01-08
NZ233766A (en) 1991-08-27
CA2017355A1 (fr) 1990-11-24
ATE83663T1 (de) 1993-01-15
DE69000641D1 (de) 1993-02-04
JPH0356412A (ja) 1991-03-12
IE63317B1 (en) 1995-04-05
JP2948271B2 (ja) 1999-09-13
NO180517B (no) 1997-01-27
ES2054289T3 (es) 1994-08-01
PT94139B (pt) 1996-12-31
IE901821L (en) 1990-11-24
FR2647343A1 (fr) 1990-11-30
IE901862L (en) 1990-11-24
PT94139A (pt) 1991-01-08
AU623779B2 (en) 1992-05-21
AU5582890A (en) 1991-01-10
GR3006655T3 (show.php) 1993-06-30
KR0163423B1 (ko) 1998-12-01
KR900017570A (ko) 1990-12-19
EP0399903B1 (fr) 1992-12-23
TW257672B (show.php) 1995-09-21
YU100790A (en) 1992-05-28
ZA903895B (en) 1991-03-27

Similar Documents

Publication Publication Date Title
FI103712B1 (fi) Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi
EE200000320A (et) Uudsed ühendid
SE9704546D0 (sv) Novel compounds
FI922364L (fi) Farmaceutiska kompositioner.
DK1036059T3 (da) Adamantanderivater
IT8920168A0 (it) Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
MY101566A (en) Pharmaceutical compositions.
MX24890A (es) Polipeptido sintetico, procedimiento par su preparacion y composicion farmaceutica que lo contiene.
DK0387821T3 (da) 2-Alkyl-4-arylmethylchinoliner, deres anvendelse og lægemidler fremstillet hermed
FI910088L (fi) Oral farmaceutisk komposition.
DE69012650D1 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
ITRM920535A1 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
FI900724A0 (fi) Anestetiska, orala kompositioner.
DE69003003D1 (de) Pharmazeutische Zusammensetzung.
Seo Recommendations for the Improvement of the Medical Licensing Examination
ATE49956T1 (de) N,n-bis-(4fluorophenyl)carbamoylacetohydroxams|ure und diese enthaltende pharmazeutische zusammensetzungen.
IT8920758A0 (it) 1,5 benzotiazepin derivati, processi per la loro preparazione e composizioni farmaceutiche.
IT1216535B (it) O_(1,2_di_0_acetilglicero_3_fosforil)etanolamina, procedimento per la sua preparazione e suo uso terapeutico.

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: RHONE-POULENC SANTE